Status:
COMPLETED
Cellular Immune Responses to Hepatitis B Virus (HBV)- Longitudinal Follow up and Natural History
Lead Sponsor:
The Alfred
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
Hepatitis B
HIV Infections
Eligibility:
All Genders
18+ years
Brief Summary
It remains unclear why some individuals are able to clear HBV from their bodies while in others HBV is a persistent infection. We plan to investigate this process by collecting blood and analysing how...
Eligibility Criteria
Inclusion
- There are two groups of patients in this study. Group A mono-infected with Hepatitis B, and those with co-infection HBV/HIV.
- Group A inclusion criteria: (also split into 6 recruiting groups)
- Acute hepatitis B
- Chronic hepatitis B, HBV DNA+ve , normal ALT , HBeAg +ve
- Chronic hepatitis B, HBV DNA +ve , normal ALT, HBeAg -ve
- Chronic hepatitis , HBV DNA +ve, increased ALT, no HBV treatment B, HBeAg +ve
- Chronic hepatitis B, HBV DNA +ve , increased ALT, no HBV treatment B, HBeAg -ve
- Chronic hepatitis B, undergoing 'flare' of hepatitis
- Group B inclusion criteria:
- To be HIV/HBV co-infected
- All patients:
- To be over 18 years
Exclusion
- Those who do not fit the inclusion criteria.
Key Trial Info
Start Date :
December 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT00168194
Start Date
December 1 2004
End Date
December 1 2009
Last Update
January 20 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Alfred Hospital, Commercial Road
Melbourne, Victoria, Australia, 3004